Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642 1671
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19461192 | MULTISPECIFIC BINDING PROTEINS THAT BIND DECTIN-1 AND TROP-2 AND METHODS OF USE THEREOF | Non-Final OA | Dren Bio Management, Inc. |
| 17767035 | COMPOSITIONS AND METHODS FOR TREATING CYTOTOXIC T CELL RESISTANT TUMORS | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18480778 | COMPOSITIONS AND METHODS FOR TARGETING AND KILLING ALPHA-V BETA-3-POSITIVE CANCER STEM CELLS (CSCS) AND TREATING DRUG RESISTANT CANCERS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 17928767 | INHIBITION OF BMI1 ELIMINATES CANCER STEM CELLS AND ACTIVATES ANTITUMOR IMMUNITY | Non-Final OA | The Regents of the University of California |
| 17796179 | METHODS FOR DIAGNOSING AND TREATING UVEAL MELANOMA | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 15734470 | COMPOSITIONS AND METHODS FOR INDUCING PHAGOCYTOSIS | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18556648 | ANTIBODY COCKTAIL FOR TREATMENT OF EBOLAVIRUS INFECTIONS | Non-Final OA | VANDERBILT UNIVERSITY |
| 17764043 | ENHANCING CANCER THERAPY TREATMENT WITH BH3 MIMETICS | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 18272906 | METHODS OF TREATING COMPLEMENT MEDIATED THROMBOTIC MICROANGIOPATHY USING AN ANTI-C5 ANTIBODY | Non-Final OA | Alexion Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy